DNER and chronic myelogenous leukemia, BCR-ABL1 positive: By combining transcriptomic and proteomic analyses, Abraham et al. showed, at the CML patient level the therapeutic potential of RG7112/7388 (HDM2 inhibitors) and CPI-203/0610 (BET inhibitors) combination to target p53 and c-MYC respectively in LSC maintenance [64].